1. Scrip
  2. >>Therapy Areas

How NGM Bio Intends To Build An Old-School Biotech

 
• By Mike Ward

NGM Biopharmaceuticals CEO Jeff Jonker discusses the company's lead program in NASH and its other R&D activities and business strategy in an interview with Scrip's Mike Ward.

Video interview
NGM Bio's Jeff Jonker talks NASH

With the hepatitis C challenge broadly solved, the leading cause of expensive liver transplants is now a disease called non-alcoholic steatohepatitis (NASH), which, not surprisingly, is attracting a lot of attention from companies looking to develop treatments.

Jeff Jonker, president of NGM Biopharmaceuticals Inc., a San Francisco-based biotech, explains to Scrip how he is positioning its lead Phase II asset, NGM282, in what is a very...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapy Areas

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 
• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.